Kura Oncology, Inc. (KURA) stock
KURANasdaqPharmaceutical PreparationsFiscal year ends December 31
$7.34−0.15 (-2.00%)
Close on Nov 18, 2026Market cap $652.97MP/E –Yield –
Kura Oncology r&d expenses
Research and development expenses are spending on new products and technology.
Kura Oncology's R&D Expenses for the twelve months ending Sep 30, 2026 was $258.44M, up 8.2% year over year. For fiscal 2025 it was $251.07M, up 47.7% from the year before. The highest annual figure on record is $251.07M in fiscal 2025.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $251.07M | +47.7% |
| FY2024 | Dec 31, 2024 | $169.97M | +47.5% |
| FY2023 | Dec 31, 2023 | $115.24M | +24.2% |
| FY2022 | Dec 31, 2022 | $92.81M | +9.6% |
| FY2021 | Dec 31, 2021 | $84.72M | +40.3% |
| FY2020 | Dec 31, 2020 | $60.40M | +26.3% |
| FY2019 | Dec 31, 2019 | $47.83M | +2.2% |
| FY2018 | Dec 31, 2018 | $46.79M | +77.0% |
| FY2017 | Dec 31, 2017 | $26.43M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $66.88M | -1.5% |
| Q2 FY2026 | Jun 30, 2026 | $61.89M | -1.4% |
| Q1 FY2026 | Mar 31, 2026 | $65.26M | +16.6% |
| Q4 FY2025 | Dec 31, 2025 | $64.41M | +23.2% |
| Q3 FY2025 | Sep 30, 2025 | $67.91M | +62.8% |
| Q2 FY2025 | Jun 30, 2025 | $62.79M | +58.0% |
| Q1 FY2025 | Mar 31, 2025 | $55.97M | +54.3% |
| Q4 FY2024 | Dec 31, 2024 | $52.27M | +60.7% |
| Q3 FY2024 | Sep 30, 2024 | $41.71M | +42.2% |
| Q2 FY2024 | Jun 30, 2024 | $39.73M | +41.0% |
| Q1 FY2024 | Mar 31, 2024 | $36.27M | +44.0% |
| Q4 FY2023 | Dec 31, 2023 | $32.53M | +43.5% |
| Q3 FY2023 | Sep 30, 2023 | $29.33M | +17.4% |
| Q2 FY2023 | Jun 30, 2023 | $28.18M | +16.2% |
| Q1 FY2023 | Mar 31, 2023 | $25.19M | +20.5% |
| Q4 FY2022 | Dec 31, 2022 | $22.67M | +8.2% |
| Q3 FY2022 | Sep 30, 2022 | $24.97M | +11.7% |
| Q2 FY2022 | Jun 30, 2022 | $24.26M | +15.1% |
| Q1 FY2022 | Mar 31, 2022 | $20.91M | +2.9% |
| Q4 FY2021 | Dec 31, 2021 | $20.96M | +19.6% |
| Q3 FY2021 | Sep 30, 2021 | $22.37M | +34.7% |
| Q2 FY2021 | Jun 30, 2021 | $21.07M | +53.9% |
| Q1 FY2021 | Mar 31, 2021 | $20.32M | +61.6% |
| Q4 FY2020 | Dec 31, 2020 | $17.52M | +30.2% |
| Q3 FY2020 | Sep 30, 2020 | $16.60M | +32.4% |
| Q2 FY2020 | Jun 30, 2020 | $13.70M | +19.7% |
| Q1 FY2020 | Mar 31, 2020 | $12.58M | +21.1% |
| Q4 FY2019 | Dec 31, 2019 | $13.46M | – |
| Q3 FY2019 | Sep 30, 2019 | $12.54M | – |
| Q2 FY2019 | Jun 30, 2019 | $11.44M | – |
| Q1 FY2019 | Mar 31, 2019 | $10.38M | – |
See a number that looks wrong?